• Jonathan Tschopp, Arnaud G L'Huillier, Matteo Mombelli, Nicolas J Mueller, Nina Khanna, Christian Garzoni, Dario Meloni, Matthaios Papadimitriou-Olivgeris, Dionysios Neofytos, Hans H Hirsch, Macé M Schuurmans, Thomas Müller, Thierry Berney, Jürg Steiger, Manuel Pascual, Oriol Manuel, Christian van Delden, and Swiss Transplant Cohort Study (STCS).
• Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
• Am. J. Transplant. 2020 Oct 1; 20 (10): 2876-2882.

AbstractImmunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%), and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts.© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

34 keywords...

hide…